Carnegie Capital Asset Management LLC Decreases Holdings in Danaher Co. (NYSE:DHR)

Carnegie Capital Asset Management LLC decreased its holdings in Danaher Co. (NYSE:DHR) by 9.9% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,984 shares of the conglomerate’s stock after selling 988 shares during the period. Carnegie Capital Asset Management LLC’s holdings in Danaher were worth $2,078,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Vontobel Holding Ltd. increased its stake in shares of Danaher by 3.0% in the fourth quarter. Vontobel Holding Ltd. now owns 341,489 shares of the conglomerate’s stock worth $79,000,000 after purchasing an additional 10,106 shares in the last quarter. River Street Advisors LLC boosted its position in shares of Danaher by 5.4% in the fourth quarter. River Street Advisors LLC now owns 1,710 shares of the conglomerate’s stock valued at $396,000 after acquiring an additional 88 shares during the period. Louisiana State Employees Retirement System bought a new position in shares of Danaher in the fourth quarter valued at approximately $9,207,000. Crestwood Advisors Group LLC boosted its position in shares of Danaher by 1.8% in the fourth quarter. Crestwood Advisors Group LLC now owns 319,898 shares of the conglomerate’s stock valued at $74,005,000 after acquiring an additional 5,613 shares during the period. Finally, Koshinski Asset Management Inc. boosted its position in shares of Danaher by 16.3% in the fourth quarter. Koshinski Asset Management Inc. now owns 1,300 shares of the conglomerate’s stock valued at $301,000 after acquiring an additional 182 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Buying and Selling

In other Danaher news, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Danaher news, Director Teri List sold 3,289 shares of the business’s stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $248.32, for a total transaction of $816,724.48. Following the transaction, the director now directly owns 19,726 shares of the company’s stock, valued at approximately $4,898,360.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 2,622 shares of the business’s stock in a transaction on Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the transaction, the senior vice president now directly owns 4,244 shares in the company, valued at $1,029,891.48. The disclosure for this sale can be found here. Insiders have sold a total of 32,957 shares of company stock valued at $8,265,802 over the last three months. 10.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of analyst reports. Raymond James raised their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Royal Bank of Canada lifted their target price on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. HSBC started coverage on shares of Danaher in a research report on Monday, December 18th. They set a “hold” rating for the company. Barclays lifted their target price on shares of Danaher from $240.00 to $260.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 10th. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $267.43.

Danaher Stock Down 0.1 %

Shares of NYSE DHR opened at $239.66 on Tuesday. The company has a quick ratio of 1.37, a current ratio of 1.68 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00. The firm’s fifty day moving average is $249.58 and its 200 day moving average is $229.84. The company has a market cap of $177.48 billion, a price-to-earnings ratio of 37.51, a PEG ratio of 3.65 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, January 30th. The conglomerate reported $2.09 EPS for the quarter, topping the consensus estimate of $1.91 by $0.18. Danaher had a net margin of 17.26% and a return on equity of 12.25%. The company had revenue of $6.41 billion for the quarter, compared to the consensus estimate of $6.10 billion. During the same period in the previous year, the firm earned $2.87 earnings per share. The firm’s revenue for the quarter was down 10.2% on a year-over-year basis. On average, equities research analysts expect that Danaher Co. will post 7.62 earnings per share for the current year.

Danaher Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 26th. Investors of record on Thursday, March 28th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. This is an increase from Danaher’s previous quarterly dividend of $0.24. The ex-dividend date is Wednesday, March 27th. Danaher’s payout ratio is presently 16.90%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.